Reaction

Lymphadenitis reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,386 reports · 85 co-occurring drugs

As of the last recalculation, Lymphadenitis appears in 2,386 FAERS reports alongside 85 co-occurring drug terms. The strongest observed disproportionality signal is ROMIPLOSTIM (PRR 54.8).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Romiplostim	91	54.8	55.1
Nevirapine	27	26.4	26.5
Zidovudine	35	23.2	23.2
Vincristine Sulfate	71	21.8	21.8
Daspone	23	20.8	20.8
Dapsone Gel, 5%	23	20.8	20.8
Rabeprazole	50	20.1	20.1
Pyrazinamide	21	19.7	19.7
Dapsone	23	19.0	19.0
Lamivudine Oral	52	18.3	18.3
Rifampicin	21	18.3	18.3
Rabeprazole Sodium	53	17.3	17.3
Dexamethasone Sodium Phosphate	20	17.3	17.3
Isoniazid	31	16.9	16.9
Lamivudine	58	16.8	16.8
Prochlorperazine	51	16.4	16.4
Drs. Clotrimazole	20	15.2	15.2
Family Wellness Clotrimazole	20	15.2	15.2
Clotrimazole Topical	20	15.2	15.2
Minocycline	20	15.1	15.1
Azathioprine	137	14.3	14.4
Fludarabine Phosphate	63	14.3	14.3
Clotrimazole	20	14.3	14.3
Filgrastim	55	13.0	13.1
Human Immunoglobulin G	30	12.8	12.9
Abacavir Sulfate	13	11.7	11.7
Moxifloxacin	18	11.2	11.2
Rifampin	18	10.8	10.8
Bendamustine Hcl	19	10.8	10.8
Itraconazole	14	10.5	10.5
Clindamycin	32	10.0	10.0
Clindamycin Phosphate	36	9.5	9.5
Cephalexin	22	8.9	8.9
Moxifloxacin Hydrochloride	20	8.7	8.7
Doxorubicin Hydrochloride	32	8.7	8.7
Rituximab	186	8.2	8.2
Amikacin	16	8.2	8.2
Doxorubicin	78	7.9	7.9
Efavirenz	10	7.9	7.9
Vitamin C	78	7.6	7.6
Anti-Thymocyte Globulin (Rabbit)	7	7.6	7.6
Canakinumab	9	7.3	7.3
Polatuzumab Vedotin	8	7.2	7.2
Lopinavir And Ritonavir	11	7.1	7.1
Atazanavir	11	6.7	6.7
Dabrafenib	16	6.7	6.7
Thiotepa	7	6.4	6.4
Obinutuzumab	12	6.4	6.4
Cyclosporine	79	6.4	6.4
Iohexol	6	6.3	6.3
Fulvestrant	23	6.1	6.1
Letrozole Tablets	33	6.1	6.1
Letrozole	42	6.0	6.0
Ganciclovir	7	6.0	6.0
Brentuximab Vedotin	7	6.0	6.0
Terbinafine Hydrochloride	6	5.9	5.9
Ganciclovir Sodium	7	5.8	5.8
Ceftriaxone	21	5.6	5.6
Linezolid	19	5.6	5.6
Ribociclib	20	5.6	5.6
Ceftriaxone Sodium	24	5.5	5.5
Trametinib	15	5.4	5.4
Tobramycin Solution	7	5.1	5.1
Tobramycin Sulfate	7	4.9	4.9
Ifosfamide	12	4.9	4.9
Dolutegravir Sodium	5	4.8	4.8
Azacitidine For	10	4.8	4.8
Pegfilgrastim	53	4.8	4.8
Azacitidine	16	4.7	4.7
Peginterferon Beta-1A	7	4.7	4.7
Cytarabine	30	4.4	4.4
Etonogestrel And Ethinyl Estradiol	11	4.3	4.3
Atezolizumab	16	3.6	3.6
Ibrutinib	32	3.5	3.5
Vemurafenib	4	2.9	2.9
Venetoclax	20	2.8	2.8
Ipilimumab	14	2.8	2.8
Isotretinoin	15	2.7	2.7
Abemaciclib	6	2.6	2.6
Durvalumab	6	2.6	2.6
Emtricitabine And Tenofovir Disoproxil Fumarate	13	2.5	2.5
Elexacaftor, Tezacaftor, And Ivacaftor	3	2.1	2.1
Drospirenone And Ethinyl Estradiol	10	2.0	2.0
Dornase Alfa	4	1.8	1.8
Bimekizumab	4	1.6	1.6

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.